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ABSTRACT
Introduction Hip fractures are associated with a high 
burden of morbidity and mortality. Globally, there is wide 
variation in the incidence of hip fracture in people aged 
50 years and older. Longitudinal and cross- geographical 
comparisons of health data can provide insights on 
aetiology, risk factors, and healthcare practices. However, 
systematic reviews of studies that use different methods 
and study periods do not permit direct comparison across 
geographical regions. Thus, the objective of this study is to 
investigate global secular trends in hip fracture incidence, 
mortality and use of postfracture pharmacological 
treatment across Asia, Oceania, North and South America, 
and Western and Northern Europe using a unified 
methodology applied to health records.
Methods and analysis This retrospective cohort study 
will use a common protocol and an analytical common 
data model approach to examine incidence of hip 
fracture across population- based databases in different 
geographical regions and healthcare settings. The 
study period will be from 2005 to 2018 subject to data 
availability in study sites. Patients aged 50 years and older 
and hospitalised due to hip fracture during the study period 
will be included. The primary outcome will be expressed as 
the annual incidence of hip fracture. Secondary outcomes 
will be the pharmacological treatment rate and mortality 
within 12 months following initial hip fracture by year. For 
the primary outcome, crude and standardised incidence 
of hip fracture will be reported. Linear regression will be 
used to test for time trends in the annual incidence. For 
secondary outcomes, the crude mortality and standardised 
mortality incidence will be reported.
Ethics and dissemination Each participating site will 
follow the relevant local ethics and regulatory frameworks 
for study approval. The results of the study will be 
submitted for peer- reviewed scientific publications and 
presented at scientific conferences.
INTRODUCTION
Hip fracture is a leading cause of high 
morbidity (30%–50% of patients lose func-
tional independence)1 2 and mortality 
(approximately 22% mortality rate at 1 year).3 
Globally, there is wide variation in the inci-
dence of hip fracture in people aged 50 years 
and older,4 ranging from an age- standardised 
rate of over 500 cases per 100 000 adults (eg, 
Denmark) to less than 100 cases per 100 000 
adults (eg, South Africa). Secular trends 
in the incidence of hip fracture have been 
suggested to follow the level of urbanisation.1
Following a hip fracture, individuals are at 
greater risk of another osteoporotic fracture 
Strengths and limitations of this study
 ► This study will involve countries/regions across Asia, 
Oceania, North and South America, Western and 
Northern Europe.
 ► The study will use a common protocol and an an-
alytical common data model to ensure consistency 
in data analysis and validity in cross- geographical 
comparisons.
 ► This study will build a global real- world data platform 
to efficiently collaborate across multiple institutions.
 ► Several databases will capture only treatments in 
the public reimbursement system. Hence, the treat-
ment rates might be underestimated by not includ-
ing patients in the private payment system.
 ► Though most of the data sources will be represen-
tative of the country- specific population, a few data 
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relative to those without a fracture. For example, in a 
study that included over 96 000 U.S. postmenopausal 
women who sustained a hip fracture, 8% had another 
clinical fracture within 1 year, 15% within 2 years, and 
25% within 5 years.5 To reduce the risk of a subsequent 
fracture, clinical guidelines from American and Euro-
pean societies for bone and osteoporosis recommend 
pharmacological treatment to reduce fracture risk after a 
hip fracture.6 7 Irrespective of guidelines, treatment rates 
in postfracture populations have been reported to be low 
in several geographical regions (16%–21% of patients 
received pharmacological treatment)8 9 and appear to 
be decreasing in both the U.S.10 and Europe.11 Given 
that pharmacological treatments have demonstrated a 
30%–50% reduction in subsequent fracture,12 many frac-
tures occurring now are preventable.13
Longitudinal and cross- geographical comparisons of 
health data can provide insights on aetiology, risk factors, 
and healthcare practices. However, global reports are typi-
cally systematic literature reviews based on studies repre-
senting a heterogeneity of methods and study periods, 
making it a challenge to examine and compare data 
between geographical regions. For hip fracture specifi-
cally, the current available reports on hip fracture inci-
dence are based on 20- year- old data in some geographical 
regions.1 14 Thus, we will investigate the global secular 
trends in hip fracture for incidence, mortality, and 
use of postfracture pharmacological treatment across 
Asia, Oceania, North and South America, Western and 
Northern Europe using a unified methodology applied 
to health records.
This study will use a common protocol and an analyt-
ical common data model (ACDM) approach to examine 
incidence of hip fracture using population- based data-
bases from different geographical regions and health-
care settings. The concept of ACDM is to standardise a 
limited set of extracted variables into a common data 
structure, allowing the use of common analytics and 
methods across multiple datasets.15 Thus, the quality of 
data analyses in each study site can be controlled by using 
standardised methodologies including definition, calcu-
lation, and standardisation. This approach will provide 
high quality and comparable data on hip fracture and, 
therefore, is superior to data from systematic reviews of 
individual studies that have applied diverse methodol-
ogies.1 4 The standardisation of estimates can facilitate 
cross- geographical comparisons. In addition, this study 
will build a global real- world data platform to efficiently 
collaborate across multiple institutions.
Hypothesis and objectives
This is an estimation study and no hypothesis will be 
tested. The study aim is to characterise hip fracture inci-
dence estimates by year and assess the trend among men 
and women aged 50 years and older within multiple 
countries. We aim to investigate the between- country and 
between- region differences in hip fracture incidence, 
mortality and pharmacological treatment rate. This may 
in turn lead to research into environmental, sociodemo-
graphic and biological explanatory factors for geograph-
ical variations in incidence and mortality of hip fracture.
Primary objective
 ► To estimate the annual incidence of hip fracture and 
evaluate the trend during 2005–2018 (objective 1).
Secondary objective
 ► To estimate the proportion of patients using a phar-
macological treatment for osteoporosis within 12 
months following their initial hip fracture by calendar 
year (objective 2).
 ► To estimate the mortality rate within 12 months 
following patients’ initial hip fracture by calendar year 
(objective 3).
Methods and analysis
The study is in the common data model development 
phase. We plan to start the data analysis in the second 
quarter of 2021. The study will end in the first quarter of 
2022.
Study design
This is a retrospective cohort study based on healthcare 
databases from multiple sites representing numerous 
geographical regions. To enable consistent analysis and 
reporting across different databases in different regions 
and healthcare settings, a common protocol, statistical 
analysis plan, and an ACDM will be used to obtain aggre-
gated data from each database. The study will consist of 
annual cohorts of patients who experience hip fracture 
from each database. Each site will convert their raw data 
into an ACDM format and apply the common statistical 
code provided by the study coordinator (University of 
Hong Kong, HKU) to perform the analysis. The study 
coordinator will not receive any patient- level data from 
the sites. Instead, each site will conduct the analysis locally 
using a centrally developed analytic plan and share aggre-
gated results with the study coordinator for the analysis of 
the pooled data.
Data source
This study will obtain aggregated data from the partici-
pating sites. All included sites will use patient- level elec-
tronic health data derived from the respective national 
or regional administrative databases, clinical databases, 
or registry databases. The study period will be from 1 
January 2005 to 31 December 2018, subject to data avail-
ability in each study site. A full list of participating sites 
and databases is provided in table 1.
The study sites will contribute aggregated data on diag-
nosis, medications, mortality and other data associated 
with hip fracture in a defined population. Depending on 
the data capability to address study questions (ie, fit- for- 
purpose), the study sites will contribute aggregated data 
for some or all of the objectives. Study sites can contribute 
incidence estimates for objective 1 for data sources of 
population- based data (ie, a defined denominator). If 
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contribute the treatment rates for objective 2. Study 
sites can contribute the mortality rates for objective 3 if 
their database contains death data or can link to death 
registries.
Study population
Patients aged 50 years and older and hospitalised due to 
hip fracture from 1 January 2005 to 31 December 2018 
will be included. We use 50 years old as a cut- off age 
because women generally enter menopause at 50 years 
old and their risk of osteoporosis and fractures after then 
increases.11 16 Patients will be excluded if they meet any of 
the following criteria: (1) had a diagnosis of hip fracture 
within 12 months before the initial hip fracture; (2) had 
missing sex or age information; or (3) had less than 12 
months continuous observation period in the data source 
prior to the start of the calendar year.
Identification of the 12 months observation period in 
the data source depends on the type of data source. For a 
database of medical claims, the patient’s enrolment date 
should precede the hip fracture by at least 12 months. 
For a database of hospital electronic medical records, the 
patient’s first event (eg, medical visit or prescription) in 
the database should precede the hip fracture by at least 
12 months.
Baseline and follow-up period
The index date will be defined as the date of admission 
for the initial hip fracture. The baseline period will be 
the 1- year period before the index date (not including 
the index date).
For the primary objective of hip fracture incidence, 
there is no follow- up of patients. For the secondary objec-
tives of post- fracture pharmacological treatment and 
mortality, each patient will be followed from the index 
date until another hip fracture episode, 12 months, 
death, disenrollment from database, 31 December 2019 
or the end of data availability in a database, whichever is 
earliest.
Outcome assessment
Hip fracture episodes will be defined as an in- patient 
diagnosis with ICD-9/-10 codes or equivalent codes of 
other diagnostic coding systems. Hip fracture is a major 
clinical event that almost always requires hospitalisation 
and is generally accurately coded.17–19 The diagnosis 
codes to identify hip fracture are subject to local clinical 
practice; the sites will use their own standard or validated 
algorithms for identifying hip fracture. The algorithms 
for hip fracture used by each site, and positive predictive 
values where available, are provided in table 2. Most data 
sources have inpatient data. If inpatient diagnoses are not 
available, for example, in databases from general practice 
(eg, Netherlands), the documented hip fracture will be 
used. Patients may have multiple hip fracture episodes 
during the study period. The initial hip fracture will be 
defined as the first occurrence of hip fracture without 
any inpatient or outpatient hip fracture diagnosis during 
the 1- year baseline period. All the hip fracture episodes 
including the initial hip fracture and any subsequent new 
episodes (contralateral or ipsilateral) will be considered 
in the calculation of hip fracture incidence. Subsequent 
new episodes are defined by no inpatient hip fracture 
diagnosis in the 180 days prior (ie, wash- out period). A 
study design schema for defining hip fracture episodes is 
illustrated in figure 1.
Pharmacological treatments for fracture prevention 
include medications that are recommended for secondary 
prevention of osteoporotic fractures. These medications 
will be identified with prescription/dispensing of the 
medications classified using the WHO Anatomical Ther-
apeutic Chemical Classification System codes whenever 
possible or equivalent codes of other drug coding systems 
used at the study site.
Date or month of death will be extracted. The cause of 
death (defined by ICD-9/-10 codes, or equivalent codes 
of other classification systems used at the study sites) will 
be included if available.
Covariate assessment
Sex and date or month of birth (or age at index date) 
will be captured. In addition, history of osteoporosis 
treatment defined as at least one prescription/dispensing 
record of any antiosteoporosis medication during the 
1- year baseline period will be captured.
For the secondary objective of treatment following 
hip fracture, patients will be considered as ‘ever use’ if 
the patient had a history of osteoporosis treatment; and 
patient will be considered as ‘new use’ if the patient did 
not have a history of osteoporosis treatment.
Statistical analysis
Microsoft Excel, R, Statistical Analysis System (SAS) will 
be used for data management and analyses. The propor-
tion of missing data will be reported, but missing data will 
not be imputed. Patients with missing age or sex informa-
tion will be excluded during the selection procedure. The 
number of study variables collected per patient is small 
and the impact of missing data is expected to be minimal 
and not likely to impact the reliability of the results.
Description of patient characteristics
Description of baseline characteristics will include age, sex 
and history of antiosteoporosis medications. Discrete vari-
ables will be summarised using frequencies and propor-
tions, and continuous variables will be summarised using 
means and SD or medians and IQR, as appropriate. Age 
will be categorised into 5- year age bands: 50–54, 55–59, 
60–64, 65–69, 70–74, 75–79, 80–84, 85 or above.
Primary objective: incidence of hip fracture
Population data will be used as the denominator (ie, 
population at risk) to calculate the annual incidence of 
hip fracture. The population of each calendar year will 
be defined as people (1) aged 50 years and older, (2) 
with known sex, (3) enrolled/registered in the database 
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period. If the population in the database is unknown, the 
national/regional population reported by the govern-
ment will be used. The mid- year population of the data-
base or the reported national/regional population aged 
50 years and older of each calendar year will be used as 
the denominator.
Similar to prior studies,20–22 the incidence (per 100 000 
persons) rate per calendar year of hip fractures will be 
calculated as the sum of new hip fracture episodes in a year 
divided by the population at risk on 1 January of that year. 
In addition, age- standardised and sex- standardised inci-
dence will be calculated to facilitate cross- geographical 
comparisons. The world population estimates in 2020 
reported by the United Nations (https:// population. 
un. org/ wpp/ Download/ Standard/ Population/) will be 
used as a standard.
A linear regression model will be used to test for time 
trends in the annual incidence in each site, assuming a 
linear trend for the hip fracture incidence, throughout 
the study period. The annual incidence as a dependent 
variable and the calendar year as a predictor variable 
will be fitted into the model. A two- tailed p<0.05 will be 
considered statistically significant.
Secondary objective: treatment proportion
Similar to a prior study,23 we will use the Kaplan- Meier 
method to estimate the treatment proportion within 3, 6 
and 12 months of fracture and 95% CI, censoring patients 
on another hip fracture episode, 12 months, death, disen-
rolment from database, 31 December 2019, or the end of 
data availability in a database; whichever is earliest.
The description of the treatment proportion will 
include (1) the treatment proportion by year of initial 
hip fracture; (2) the treatment proportion for new 
medication users (treatment- naive), defined as those with 
no prescription filled for osteoporosis medications within 
12 months prior to their hip fracture (ie, during the base-
line period); and (3) the treatment proportion by the 
type of treatment (see table 3 for details).
Secondary objective: one-year mortality following hip fracture
Similar to a prior study,21 the 1- year mortality (per 100 
patients) rate per calendar year of initial hip fracture will 
be calculated as the sum of patients who died of any cause 
during the 12- month follow- up period divided by the sum 
of patients with an initial hip fracture. An additional 
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analysis using the Kaplan- Meier method to account 
for censoring will be included as well. In addition, the 
mortality will be ascertained for the first 3 months and 
the first 6 months after the initial hip fracture. Age- 
standardised and sex- standardised mortality will be 
calculated to facilitate cross- geographical comparisons. 
The world population estimates in 2020 reported by the 
United Nations will be used as a standard.
Additional analysis
Sensitivity analyses will be performed to evaluate the 
robustness of the results from the primary analysis. In the 
primary analysis, a wash- out period of 180 days is used to 
define a new episode of hip fracture. In the sensitivity anal-
ysis, a shorter (90 days) and a longer (365 days) wash- out 
period will be used. In addition, the requirement of at 
least 12- month continuous observation period may not 
capture fractures in a given year among those with less 
than a year of prior observation. Thus, a sensitivity anal-
ysis by removing this requirement will be conducted to 
evaluate if this requirement affects the estimates.
Fractures may occur in patients for reasons other than 
osteoporosis. In databases where the information is avail-
able, we will repeat the analysis in the subgroup excluding 
patients with any of the following criteria: (1) concur-
rent diagnosis of high trauma fractures (high trauma 
is defined as vehicle accident or fall from greater than 
standing height); (2) bone metastasis during the 1- year 
baseline period; (3) Paget’s disease during the 1- year 
baseline period; or (4) osteogenesis imperfecta during 
the 1- year baseline period.
Given the high mortality in the first year after hip frac-
ture, death could be a competing risk event leading to 
overestimation of treatment probability. Therefore, a 
competing risk analysis using the cumulative incidence 
function approach will be performed to estimate the 
marginal probability of treatment with adjustment for 
competing risk of death.
Age- specific and sex- specific estimates of hip fracture 
incidence and mortality will be provided in 5 years age 
bands: 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 
85 or above.
Analytical common data model
The ACDM will be created to increase validity and consis-
tency of data analysis using multidatabases. The sites 
will convert de- identified subject- level data into table 
formats in ACDM and use standard programming codes 
to conduct the statistical analysis and generate aggregate- 
level data. The ACDM will be codeveloped by HKU and 
Amgen. R and SAS programming codes will be developed 
by the programming team in HKU and Amgen, respec-
tively. To ensure quality assurance, at least two program-
mers will be involved to cross check the codes. The R and 
SAS programming codes will run on the same sample 
dataset and the results should be a 100% match. It is 
expected that the development of ACDM and program-
ming codes will take around 2–3 months. Since the data 
structure varies across databases, HKU will discuss with 
the sites if any modification of the ACDM and program-
ming codes will be needed. All the site- specific modifi-
cations will be documented. Sharing of the script as 
open- source code will be subject to journal requirement 
when the results are published.
Sample size
The estimated sample size in the databases ranges from 
several hundred hip fractures per year to tens of thou-
sands of hip fractures per year. For example, the data 
source for Hong Kong, a region of 7.2 million people 
with 2.8 million adults aged 50+, has approximately 9300 
hip fractures per year in adults aged 50+ (a crude rate of 
330 fractures per 100 000). The estimated samples sizes 
for each database are provided in table 4.
Limitations
In general, most of the databases were built for adminis-
trative or reimbursement purposes rather than research 
purposes. The databases represent a variety of data 
sources, healthcare settings, and coding practices each 
of which will have different features and limitations. The 
strengths and limitations of different type of databases 
have been discussed elsewhere.24 The features of the data-
bases in this study are shown in table 1. A majority of data-
bases have a high (over 90%) population coverage and 
official census data will be used as denominator. Data-
bases with lower population coverage will use the actual 
number of individuals in the databases as denominator 
(Japan, UK and USA). The databases in Italy do not link 
to national/regional death registry. National prescription 
data are only available in Australia, Denmark, Finland, 
New Zealand, South Korea and Taiwan.
Measurement errors/misclassifications
The study will use prescription/dispensing data to assess 
treatment, which is only a proxy for the patient taking 
their medication. The actual treatment with certain medi-
cations, such as oral bisphosphonates, may therefore be 
overestimated. In addition, use of zoledronic acid is not 
expected to be captured in all databases. For example, in 
countries where zoledronic acid is administered in hospi-
tals or outpatient clinics, some databases do not readily 
capture medication administered in the hospital setting. 
In such circumstances, patients may be misclassified as 
having no treatment even though they were exposed to 
zoledronic acid.
The database for Hong Kong does not capture clin-
ical records from private clinics/hospitals, though it is 
expected that most of the cases will be admitted to public 
hospitals via emergency service.
Several databases will capture only treatments in the 
public reimbursement system (Hong Kong, South Korea, 
Taiwan and others); hence, the treatment rates might be 
underestimated by not including patients in the private 
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cannot be captured in the reimbursement system, leading 
to potential underestimation of treatment rates.
Information bias
Since hip fracture is a major clinical event that almost 
always requires hospitalisation, only hospital diagnoses of 
hip fracture will be considered in most databases (except 
when inpatient diagnoses are not available in the data-
base). Fractures may occur in patients for reasons other 
than osteoporosis (eg, trauma, bone metastasis, Paget’s 
disease, osteogenesis imperfect). Eligibility criteria for 
the study have been kept broad for the practical purpose 
of applying consistent definitions across multiple data-
bases. To inform interpretation, we will conduct a sensi-
tivity analysis excluding patients with these four criteria in 
those databases able to support the analysis.
Selection bias
All patients who fulfil the eligibility criteria in each data-
base will be included. A majority of the databases cover 
over 90% of the population (eg, Finland, Hong Kong, 
South Korea and others; see table 1) and therefore selec-
tion bias is not expected to be a major issue in these 
databases. However, a few data sources will be represen-
tative of local hospitals with limited population coverage 
(eg, Thailand), leading to potential selection bias. For 
instance, the Japanese database has no subjects aged 
75+ years and limited number of subjects aged >60 years 
compared with national statistics. Given that the Japan 
data source does not contain the oldest adults at highest 
risk for hip fracture, the current protocol will provide an 
underestimation of the overall population incidence of 
hip fracture in Japan. However, the age subgroup anal-
ysis will provide a reasonable measure of incidence in 
the population under 75 years old. Therefore, we will 
exclude Japan data in the estimation of overall popula-
tion incidence but will include it only in the age- specific 
analysis. Although these sites have limited data for popu-
lation estimates, the results are still informative for cross- 
geographical comparisons. More importantly, the site 
participation in this study can facilitate global coopera-
tion, and also raise the awareness of the need for stan-
dardised high- quality national data for research.
Patient and public involvement
The study will involve retrospective analysis of secondary 
data collected from databases. Patients are deidentified 
and there is no direct patient involvement. However, 
several researchers involved in this study routinely 
consult with patients in the design, development and 
reporting of research at a national level. Patients may be 
involved in presentations and dissemination of the results 
at a national level. Each participating site will be respon-
sible for obtaining ethical clearances in accordance with 
current regulations within their local jurisdiction.
Ethics and dissemination
Each participating site will follow the relevant local ethics 
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of ethics approval in each site is listed in online supple-
mental table. All data to be used in this study are taken 
from existing anonymised records. In addition, partici-
pating sites will only share aggregated data with the study 
coordinators.
The results of the study will be submitted for peer- 
reviewed scientific publications and presented in scien-
tific conferences. Authorship of any publications resulting 
from this study will be determined on the basis of the 
International Committee of Medical Journal Editors 
Recommendations for the Conduct, Reporting, Editing, 
and Publication of Scholarly Work in Medical Journals.
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